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Abstract 
Epidermolysis bullosa (EB), the paradigm of heritable skin fragility disorders, is associated with 
mutations in as many as 20 distinct genes. One of the clinical variants, recessive dystrophic EB 
(RDEB), demonstrates sub-lamina densa blistering accompanied by alterations in anchoring 
fibrils due to mutations in COL7A1. In this study, we characterized a patient with widespread 
connective tissue abnormalities including skin blistering similar to that in RDEB. Whole exome 
sequencing, combined with genome-wide homozygosity mapping, identified a homozygous 
missense mutation in PLOD3 encoding lysyl hydroxylase 3 (LH3). No mutations in COL7A1, 
the gene previously associated with RDEB, were detected. The level of LH3 was dramatically 
reduced in the skin and fibroblast cultures from the patient. The blistering in the skin occurred 
below the lamina densa and was associated with variable density and morphology of anchoring 
fibrils. The level of type VII collagen expression in the skin was markedly reduced. Analysis of 
hydroxylysine and its glycosylated derivatives (galactosyl-hydroxylysine and glucosyl-
galactosyl-hydroxylysine) revealed marked reduction in glycosylated hydroxylysine. 
Collectively, these findings indicate that PLOD3 mutations can result in a dystrophic EB-like 
phenotype in the spectrum of connective tissue disorders and add it to the list of candidate genes 
associated with skin fragility.  
 
Keywords: Epidermolysis bullosa; lysyl hydroxylase 3; PLOD3, type VII collagen, collagen 
glycosylation  
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Introduction 
Phenotypic and genetic heterogeneity of EB 
Epidermolysis bullosa (EB), a group of heritable skin fragility disorders, manifests with 
blistering and erosions leading to ulcers with poor healing tendency [1]. EB is divided into four 
broad categories based on the level of tissue separation within the dermal-epidermal basement 
membrane zone as a result of external trauma. These different subtypes of EB demonstrate 
extensive phenotypic variability, which, to a large part, reflects genetic heterogeneity, and as 
many as 20 distinct genes have so far been shown to be associated with different forms of EB [2-
5].  
One form of EB is the recessive dystrophic EB (RDEB), which in most severe cases 
manifests with tense blisters which can develop into non-healing ulcers prone to infections and 
later in life lead to development of aggressive squamous cell carcinomas resulting in early 
demise [1, 6]. Tissue separation in the dystrophic form of EB is below the lamina densa within 
the upper papillary dermis at the level of anchoring fibrils. Anchoring fibrils, which consist of 
type VII collagen, can be reduced in number, morphologically altered or entirely absent in 
RDEB as a result of mutations in the COL7A1 gene which encodes the type VII collagen 
precursor polypeptides [7]. Thus far, COL7A1 is the only gene that has been implicated in the 
pathobiology of dystrophic forms of EB. 
 
Type VII collagen and the anchoring fibrils 
Type VII collagen is initially synthesized by basal keratinocytes and dermal fibroblasts as a 290-
kDa polypeptide, and three of these chains assemble intracellularly into a triplex molecule 
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through association of their carboxy-terminal ends, followed by folding of the collagenous 
domain into stable triple-helical conformation at physiological body temperatures in a process 
requiring prolyl-4-hydroxylation [7]. In addition, a select number of lysyl residues are 
hydroxylated to form hydroxylysyl residues, and some of them are subsequently glycosylated in 
a step wise fashion to form either galactosyl-hydroxylysine (GHL) or glucosyl-galactosyl-
hydroxylysine (GGHL) residues. Following intracellular processing, type VII collagen molecules 
are secreted into the extracellular space where they assemble into a centro-symmetric dimer 
arrangement with tail-to-tail interactions through their carboxy-termini [8].  Subsequently, a 
large number of such dimer molecules laterally aggregate to form anchoring fibrils which 
associate through their amino-terminal ends with the components of the lamina densa to form U-
shaped structures which entrap type I collagen molecules within the upper papillary dermis [9]. 
Thus, the anchoring fibrils tether the dermal-epidermal basement membrane to the underlying 
dermis.  
 
Post-translational modification of collagens 
Hydroxylation of lysyl residues to form hydroxylysine residues is an essential post-translational 
modification catalyzed by lysyl hydroxylases (LH), a family of four different isoforms: LH1, 
LH2a, LH2b and LH3 (the latter one also known as procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 3; PLOD3) [10]. Subsequently, certain hydroxylysine residues in the Y position of 
the repeating gly-X-Y sequence of collagen polypeptides become O-glycosylated in the 
intracellular milieu classically by two separate enzymatic activities, collagen 
galactosyltransferase and collagen glucosyltransferase which sequentially transfer UDP-
galactose to peptidyl hydroxylysine and UDP-glucose to galactosyl-hydroxylysine residues, 
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respectively [11].  Interestingly, however, in addition to its ability to hydroxylate lysyl residues, 
LH3 is also able to glycosylate hydroxylysine residues. LH3 is also the only LH which is 
secreted and present in the extracellular space [12, 13]. Recent studies utilizing immune co-
precipitation and Western blotting analyses as well as in situ proximity ligation assay have 
demonstrated a direct interaction between LH3 and type VII collagen [14]. Immunoelectron 
microscopy and morphometric measurements utilizing antibodies raised against the amino- and 
carboxy-termini of type VII collagen as well as the amino-terminus of LH3 have demonstrated 
immune labeling beneath the epidermis where LH3 was shown to be localized to two main 
compartments: (a) over the lamina densa/basement membrane directly beneath 
hemidesmosomes, and (b) in the sub-lamina densa region in the area corresponding to the central 
collagenous domain of type VII collagen [14]. However, whether LH3 is catalytically active in 
these extracellular sites and whether it catalyzes hydroxylation and subsequent glycosylation of 
lysyl residues in type VII collagen is currently unknown. 
 The interest to study LH3 in EB, in addition to its co-localization with type VII collagen 
at the dermal-epidermal junction, was increased by demonstration that the level of LH3 is 
significantly reduced in RDEB patients’ skin and in keratinocytes derived from these patients 
[14]. Conversely, overexpression of type VII collagen in RDEB cells resulted in increased LH3 
secretion, suggesting functional inter-relationship between LH3 and type VII collagen.  
 
LH3 deficiency leads to widespread connective tissue abnormalities 
Considering the fact that LH3 potentially participates in post-translational modification of all 
collagens, deficiency in this protein could be predicted to result in widespread connective tissue 
disorders. This, in fact, has been demonstrated in Plod3 knock-out mice which demonstrate 
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connective tissue perturbations, including changes in collagen fibers in the skin [15]. In addition, 
LH3 deficiency in patients with mutations in PLOD3 has been shown to result in severe 
morbidity as a result of features of a number of known collagen disorders, including 
musculoskeletal abnormalities [16]. 
 In this report we describe a patient with biallelic mutations in PLOD3, the gene encoding 
LH3. The patient demonstrated widespread connective tissue abnormalities, including skin 
blistering similar to that noted in RDEB, reduced type VII collagen expression, and paucity of 
anchoring fibrils, features that have not been emphasized in the previous cases. . 
 
RESULTS 
We have explored the molecular basis of EB patients in Iranian, largely consanguineous, families 
by next generation sequencing approaches, including utilization of a gene-targeted sequencing 
panel consisting of 21 skin fragility-associated genes as well as by whole exome sequencing 
(WES) [17-20]. In a consanguineous family, the proband was found to have extensive connective 
tissue abnormalities, including skin blistering and erosions since birth, consistent with dystrophic 
forms of EB (Figure 1). The parents were clinically normal, suggesting autosomal recessive 
inheritance, and there was evidence of consanguinity in the family (Figure 1a).  
 
Case Report  
The proband, a 4.5-year-old male, was born to healthy Iranian Baloch second cousins once 
removed (Figure 1a). He was referred to our laboratory for genetic testing with an initial 
diagnosis of Escobar syndrome and epidermolysis bullosa. At the first visit, a slender male, with 
developmental delay, manifested with musculoskeletal involvement  including scoliosis, flexion 
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contractions in elbows and carpometacarpal joints, webbing across the second interphalangeal 
joint of the left hand, prominently enlarged knee and elbow joints, short legs, talipes 
equinovarus, and reduced muscle mass (Figure 1e-h).  He had pterygia of the neck, axilla, 
antecubital, popliteal, digital and intercrural areas. The thumbs were abnormally folded over 
palm. Skin creases on both palms were reduced. In addition, trauma-induced skin blisters over 
the prominent body areas, particularly on elbows, feet, knees, and ears with history of delayed 
wound healing, were noted (Figure 1b, c). He had dystrophic nails in his feet, but his hair and 
teeth were normal. The parents claimed that the nails were rapidly growing. His height, weight 
and head circumference were 96 cm (<3
rd
 centile), 10 kg (<3
rd
 centile) and 46 cm (<2
nd
 centile), 
respectively. Ophthalmologic examination showed amblyopia and strabismus, in addition to his 
neonatal ophthalmologic findings (see below).  
The patient was born at term following normal vaginal delivery without complications 
during pregnancy. His birth weight, height, and head circumference were within the normal 
range, 2,650 g, 48 cm and 33 cm, respectively. Milestones were delayed; rolled over at 5 months, 
sat at 8 months, stood at 2 years, walked at 3 years and started saying his first works at the age of 
three years. He now at the age of 4.5 years has a vocabulary of 50 words. The patient was born 
with a right eye cataract, ptosis, severe myopia, flat face profile with a long philtrum, low set 
ears, and short nose with anteverted nares. Ophthalmologic surgery to correct unilateral ptosis 
was performed at 10 months of age. There were two complicated pregnancies in the family, one 
before and one after the proband’s birth (Figure 1a). The first one was terminated at 12 weeks 
due to intrauterine growth failure, and the second one at 18 weeks due to underdevelopment of 
the neural system. The proband had neonatal hyperbilirubinemia (total bilirubin 19; normal level 
<1 mg/dl) at the first week of his life, relieved by phototherapy. To rule out kernicterus, brain 
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magnetic resonance imaging studies were performed revealing hypersignal areas in basal ganglia 
favoring kernicterus, as well as another hypersignal region in the left parietal brain suggesting 
hemorrhage and calcification.   
   To work up syndromic diseases, plain chest radiography and chest computed tomography 
(CT) scan were conducted at 1 month of age. The proband had right diaphragmatic eventration 
seen in spiral CT scan of the thorax without intravenous contrast, and there was a large soft 
tissue density in medial and anterior basal aspects of right hemithorax with midline and leftward 
extension, displacing the heart upwards, likely attributed to herniation of hepatic parenchyma 
into the thorax in the context of a diaphragmatic hernia (Morgagni) or severe eventration (Figure 
1d). Only a small part of right lobe of liver was seen in the right subdiaphragmatic space. 
Diaphragmatic eventration disappeared with aging without intervention. His echocardiography 
was normal with 60% ejection fraction at 9 months of age. In addition, the patient had normal 
electrodiagnostic study in both upper limbs, with no evidence of peripheral nerve lesion or 
polyneuropathy at 18 months of age. There was normal electromyography in bilateral flexor 
carpi ulnaris muscles. In comparison with a similar case previously presented [16], our patient 
did not show any evidence of cutaneous hemorrhage, vascular aneurysms, sensory neural hearing 
loss or coarse hair, some of which had developed in the previous case at an older age (Table S1).  
 
Whole exome sequencing identifies a pathogenic missense mutation in PLOD3 
Targeted multi-gene sequencing array consisting of 21 skin fragility-associated genes was first 
applied to DNA from the proband and his parents. No pathogenic mutations in these 21 
candidate genes previously associated with EB were found. It should be noted that careful 
examination of previously reported EB-associated genes, and specifically COL7A1, failed to 
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reveal pathogenic mutations, including large deletions. The proband’s DNA was subsequently 
submitted to WES, which identified a total of ~134,000 sequence variants (Figure 2). Following 
bioinformatics filtering, which considered exonic/splicing variants only, removed synonymous 
sequence variants, and identified homozygous/compound heterozygous variants with minor 
allelic frequency (MAF) <0.001, reduced the number of annotated, potentially pathogenic 
variants to 16 (Figure 2b). 
Homozygosity mapping using a single nucleotide polymorphism panel of 640,000 
markers identified several regions of homozygosity (ROH), including one of ~45 Mb in the 
patient’s DNA in chromosome 7 (Figure 2a). This homozygosity block was not present in 
clinically healthy parents. There was no ROH associated with chromosome 3 which harbors the 
COL7A1 locus in the region 3p21.3. Overlapping of the 16 variants identified by WES with the 
45 Mb ROH reduced the number of potential candidate genes containing homozygous mutations 
to eight (Table S2). Subsequently, segregation analysis of the variants in the family and 
phenotypic matching with the known functions of the genes suggested PLOD3 as the candidate 
gene. Next generation sequencing identified a homozygous mutation in the PLOD3 gene 
(NM_001084), c.1880T>C; p.Leu627Pro, and this was confirmed by bidirectional Sanger 
sequencing (Figure 2c). The Leu627 residue is highly conserved through evolution between H. 
sapiens and D. melanogaster (MutationTaster), and this missense substitution was predicted to be 
pathogenic by bioinformatics prediction programs (ANNOVAR) [21]. The parents were shown 
by Sanger sequencing to be heterozygous carriers of the p.Leu627Pro mutation (Figure 2c). 
Three-dimensional protein modeling localized the p.Leu627Pro mutation to the LH domain of 
LH3, responsible for lysyl hydroxylase activity which is dependent on the presence of Fe
2+
 and 
2-oxoglutaric acid (Figure 2d). Western blotting of protein synthesized by fibroblasts established 
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from the skin of the patient showed markedly reduced, by ~80%, levels of LH3, when compared 
to three unaffected controls (Figure 2e, f). It should be noted, however, that the PLOD3 mRNA 
levels in the patient’s fibroblasts measured by whole-transcriptome sequencing and confirmed by 
RT-PCR, were the same as in control cells, indicating post-translational consequences of the 
mutation on LH3 expression. However, the expression of type VII collagen was reduced 
significantly. There are no obvious changes in expression of types I, IV, V, and VI collagens 
(Figure 2g). 
 
Consequences of the PLOD3 mutation at structural level 
Histopathologic examination of the skin adjacent to a blister revealed separation at the dermal-
epidermal junction, with no evidence of inflammation (Figure 3a). Ultrastructurally, the level of 
cleavage was shown to be below the lamina densa (Figures 3b). Transmission electron 
microscopy (TEM) of the patient’s skin revealed changes in the lamina densa, and specifically, 
while in some parts of skin the lamina densa appeared relatively intact, in other areas it was 
interrupted and fragmented (Figure 4). TEM revealed a variable number and altered morphology 
of anchoring fibrils in both intact and blistered skin (Figure 5). In areas with no sub-lamina densa 
cleavage, there were a number of well-formed anchoring fibrils, while in other sections, the 
dermal-epidermal junction was intact but the sub-lamina densa region was devoid of anchoring 
fibrils. In some areas, there was extensive sub-lamina densa cleavage with only a few, thin, wisp-
like structures with no clearly discernable anchoring fibrils present (Figure 5). 
Histopathology at low magnification demonstrated flattened appearance of the dermal-
epidermal junction and dense appearance of the papillary dermis (Figure 6a). Several fibroblasts 
were found to be present close to the dermal-epidermal junction embedded within the dense, 
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homogeneous upper dermis consisting of densely packed individual collagen bundles as 
observed by histopathology and TEM (Figure 6b, c). Many of the fibroblasts displayed dilated 
endoplasmic reticulum and prominent vesicles close to the cell membrane, consistent with high 
biosynthetic activity. Collectively, these findings were suggestive of a blistering disorder with 
sub-lamina densa tissue separation and fibrosis overlapping with the ultrastructural features of 
RDEB.  
  
Reduced Expression of LH3 and Type VII Collagen in the Skin 
Immunofluorescence microscopy with an antibody specific for LH3 showed its presence in a 
punctate pattern at the dermal-epidermal junction in the control skin, while it was completely 
absent in the patient’s skin (Figure 7a). Staining for type VII collagen with a monoclonal 
antibody, revealed bright linear staining in control skin, while in the patient’s skin the staining in 
the blistered area showed markedly attenuated amounts of type VII collagen, present primarily in 
the roof of the blister (Figure 7a).  
Additional immunostaining experiments with antibodies recognizing type IV and XVII 
collagens, laminin 332 (γ2-subunit), 4 integrin and plectin confirmed that the blistering 
occurred below the lamina densa (Figure 7b). Staining for keratins 1, 5, 10 and 14 revealed 
essentially normal epidermal pattern with somewhat attenuated staining (Figure 7c). Thus, 
antigen mapping established the plane of cleavage below the lamina densa. In addition, the 
intensity of staining for type XVII collagen was attenuated while the staining for type IV 
collagen appeared unaltered as compared to control (Figure 6b). 
Quantitation of the presence of type VII collagen by Mean Fluorescence Intensity (MFI) 
assay [22] revealed consistent reduction, yet considerable variability, in the presence of type VII 
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collagen in different parts of the skin of the proband. In some areas, the intensity was reduced 
only by ~30%, while in some areas, type VII collagen was present only at the level of ~23% of 
the control (Figure 8). In general, the areas showing the lowest level of expression of type VII 
collagen were characterized ultrastructurally by a marked reduction or absence of anchoring 
fibrils (see above).   
Collectively, the histopathologic, ultrastructural, expression profile, and 
immunofluorescence findings in the proband’s skin demonstrated features of dystrophic forms of 
EB, a disease previously associated with mutations in the COL7A1 gene [7]. As indicated above, 
no pathogenic homozygous or compound heterozygous mutations in COL7A1 were identified by 
EB-gene targeted sequencing panel or WES, suggesting that PLOD3 is the second gene 
harboring mutations in patients with RDEB-like clinical presentation. 
 
Reduced Glycosylation of Urinary Hydroxylysine  
Since LH3 displays both lysyl hydroxylation and hydroxylysyl glycosylation activities [15], one 
of the potential consequences of PLOD3 mutations would be reduced hydroxylysine and/or 
galactosyl-hydroxylysine (GHL) and glucosylgalactosyl hydroxylysine levels (GGHL) in 
collagens. To explore this possibility, the relative levels of lysine, hydroxylysine, GGHL and 
GHL in the form of collagen-derived pyridinoline compounds were determined in the urine of 
the proband and his parents by liquid chromatography. First, quantitation of the ratio of total 
hydroxylysine/lysine did not reveal differences between the patient and his parents (Figure 9). 
Furthermore, the ratio in the 4.5-year old patient was within the limits of age-matched controls 
(3-5 years). However, significantly decreased levels of glycosylated hydroxylysine derivatives 
were noted in the proband with a concomitant relative increase in hydroxylysine (Figure 9). As a 
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consequence, the ratio of (GGHL + GHL)/HL in the proband was reduced to about 17% of that 
measured in his parents, a value well below the age-matched controls. Finally, the ratio of 
GGHL/GHL was unaltered as compared to controls. .  
 
DISCUSSION 
In this study, we have demonstrated sub-lamina densa blistering with markedly reduced type VII 
collagen in the skin of a patient with a homozygous missense mutation in PLOD3. In addition to 
skin blistering, the proband demonstrated extensive joint contractures, skeletal abnormalities and 
reduced growth. Previously, a family with mutations in PLOD3 has been reported, the proband 
being compound heterozygous for c.668A>G, p.Asn223Ser; c.2071delT, p.Cys691AlafsX9 [16]. 
These mutations resided in different parts of LH3, responsible for lysyl hydroxylation and 
hydroxylysine glycosylation activities, respectively (see Figure 2d). The patients in the previous 
study had an extremely complex phenotype, including deafness, myopia, arterial ruptures, 
osteopenia, joint contractures, bone fractures, and cataracts, as well as clinically observed skin 
blistering, apparently reflecting the deficiency in both lysyl hydroxylation and glycosylation of 
hydroxylysyl residues. In contrast, our patient had a homozygous mutation interfering primarily 
with the glycosylation activity, which may explain somewhat milder phenotype, although it 
should be noted that our patient was much younger (4.5 years) than those reported previously (up 
to 14 years of age). Nevertheless, in both cases there were a number of extracutaneous 
manifestations attesting to the multisystem consequences of the PLOD3 mutations.  
Interestingly, an earlier study reported deficiency of galactosylhydroxylysyl-
glucosyltransferase activity in a large Finnish family with autosomal dominant epidermolysis 
bullosa simplex [23]. Most of the affected members of the family showed low enzymatic activity 
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in serum, skin and cultured skin fibroblasts, and there was a markedly reduced urinary excretion 
of GGHL. This decrease in glucosyltransferase activity was limited to this enzyme, and lysyl 
hydroxylase and hydroxylysyl galactosyltransferase activities, as determined in skin biopsy 
specimens, were normal [23]. How the deficiency in galactosylhydroxylysine-
glucosyltransferase, an enzyme primarily involved in post-translational modification of collagens 
might cause EB simplex is unclear, but it could serve as a modifier of the severity of EB 
phenotype [15] as a specific defect in glycosylation of epidermal cell membranes has been 
reported in EB simplex [24].  Previously, skin blistering has also been reported in patients with 
extensive pulmonary and renal involvement due to mutations in the ITGA3 gene encoding 3 
subunit of the 31 integrin complex [25]. These observations suggest the concept of 
classification of skin fragility disorders in the spectrum of EB into two distinct categories: 
syndromic and non-syndromic with prognostic implications [26]. In the latter category, the 
epithelia of skin and various mucous membranes are primarily affected, while in the first one, the 
disease manifests in addition to skin in a number of extracutaneous tissues and internal organs in 
a multisystem fashion. 
It should be noted that the mutation, p.Leu627Pro, was shown to reside within the LH 
domain responsible for lysyl hydroxylation, yet the ratio of urinary hydroxylysine/lysine was not 
altered. This discrepancy could be explained by the suggestion that this nonsense mutation does 
not interfere with the catalytic activity of LH3, but rather results in conformational changes 
predisposing the protein to degradation and loss of both lysyl hydroxylation and hydroxylysyl 
glycosylation activities. In such case, lysyl hydroxylation could be compensated by other 
members of the LH family (LH1). At the same time, LH3 has very low, if any, galactosyl-
hydroxylysyl transferase activity while it is the major protein responsible for 
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galactosylhydroxylysyl glucosyltransferase activity [27], and the reduced hydroxylysine 
glycosylation as a result of PLOD3 mutation is likely to reflect loss of LH3 protein, provided 
that other proteins, such as ColGalT1 and ColGalT2 (previously known as GLT25D1 and 
GLT25D2), do not significantly contribute to the glycosylation reaction.  
 In summary, our study demonstrates the consequences of a homozygous PLOD3 
mutation in a patient with extensive connective tissue abnormalities, including skin fragility with 
RDEB-like phenotype. Histopathology and TEM revealed sub-lamina densa blistering, and the 
anchoring fibrils were perturbed with deficiency in type VII collagen. In addition to skin 
blistering, there was evidence of fibrosis in the upper papillary dermis, a feature of RDEB [28, 
29]. It should be emphasized the WES did not reveal pathogenic mutations in COL7A1, and there 
was no ROH associated with chromosome 3 which harbors the COL7A1 locus. While this study 
was focusing on blistering phenotype and type VII collagen in this complex patient, it should be 
noted that all collagens undergo post-translational modifications, including glycosylation of 
hydroxylysine residues, and defective post-translational modifications of other members of the 
collagen family, such as type I, III, V and VI, are likely to explain the widespread 
musculoskeletal findings in these patients with complex phenotype. The physiological role of 
glycosylated hydroxylysine specifically in type VII collagen is not clear. One could speculate 
that deficient glycosylation of type VII collagen may interfere with the extracellular assembly of 
the anchoring fibrils or compromise their stability rendering them subject to degradation. We 
also noted that expression of type XVII collagen at the basement membrane zone of our patient’s 
skin was somewhat attenuated, possibly reflecting consequences of under-glycosylation of this 
collagen as well. However, expression of type IV collagen, the type particularly rich in 
glycosylated hydroxylysine residues [30, 31], was essentially normal in our patient’s skin. This is 
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at variance with observations in studies examining LH3 knock-out mouse embryos and 
embryonic fibroblasts which revealed that loss of hydroxylysine glycosylation prevents the 
assembly and secretion of type IV and VI collagens, with deleterious changes in the deposition 
and organization of the extracellular matrix [15]. Collectively, these findings, together with a 
previous publication of similar cases [16], indicate that a novel gene, PLOD3, can harbor 
mutations in the dystrophic forms of EB, and adds this gene to the growing list of candidate 
genes associated with skin fragility disorders in the spectrum of EB.  
 
MATERIALS AND METHODS 
Patient data 
This study was approved by the Institutional Review Board of the Pasteur Institute of Iran, and 
all subjects and the parents of children gave written informed consent to participate in research 
and to publish their image. Originally, 362 extended families were included for mutational 
analysis. Criterion for study inclusion was a tentative diagnosis of epidermolysis bullosa (EB) 
based on history of neonatal cutaneous blistering suggestive of a genetic blistering disorder. One 
patient was found to have a trauma-induced blistering with clinical impression of dystrophic EB 
in addition to other systemic manifestations as described in this study.  
Whole exome sequencing 
DNA was extracted from peripheral blood lymphocytes of the proband by salting out method. 
DNA concentration was measured using a Qubit 3.0 fluorometer (Life Technologies, Carlsbad, 
CA, USA). The qualified genomic DNA samples were randomly fragmented by Covaris and the 
size of the library fragments was distributed predominantly between 150 to 200 base pairs (bp). 
Adapters were then ligated to both ends of the resulting fragments. The adapter-ligated templates 
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were purified by the Agencourt AMPure SPRI beads and fragments with insert size about 176 bp 
were excised. Extracted DNA was amplified by ligation-mediated PCR (LM-PCR), purified, and 
hybridized to the SureSelect Biotinylated RNA Library (BAITS) for enrichment. The hybridized 
fragments were bound to strepavidin beads whereas non-hybridized fragments were washed out 
after 24 h. Captured LM-PCR products were subjected to Agilent 2100 Bioanalyzer to estimate 
the magnitude of enrichment. Each captured library was then loaded on HiSeq2000 platform, and 
high-throughput sequencing for each captured library was performed to ensure that each sample 
met the desired average sequencing depth.  
Raw image files were processed by Illumina Software 1.7 for base-calling with default 
parameters and the sequences of each individual were generated as 90/100 bp pair-end reads. 
The bioinformatics analysis was applied to the sequencing data (“raw data”) which was 
generated from the Illumina pipeline. First, the adapter sequence in the raw data was removed, 
and low-quality reads with too many uncertain nucleotide reads or low base quality were 
discarded. This step produced the “clean data”. Secondly, Burrows-Wheeler Aligner (BWA) was 
used for alignment. Read groups were added, duplicates were marked and the reads were sorted 
using Picard (http://broadinstitute.github.io/picard). After these processes, the final BAM files 
were used for variant calling using the GATK haplotype caller
 
to identify both single nucleotide 
variants (SNVs) and indels. Candidate variants were then annotated using ANNOVAR software. 
ANNOVAR MetaSVM scores, based on several predictive bioinformatics tools, including SIFT, 
PolyPhen2, MutationTaster and MutationAssessor, were used to identify variants as deleterious. 
Variant interpretation 
SNVs and copy number variants (CNVs) were examined using the annotated CSV files of WES 
from the proband. The sequence variants were filtered from the VCF files for missense, 
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nonsense, and splice site-affecting variants. Indel variants were filtered for exonic in-frame 
insertions and deletions, frameshift mutations, and gained or lost start or stop codon. 
Additionally, only variants with 1000 Genomes database total frequencies of <0.001, or those 
without frequency data available, were examined. These variants were then overlapped with runs 
of homozygosity (ROH) in the patient. Considering the given phenotype, segregation analysis in 
the family, and the presence of several ROH in this patient with consanguineous parents, we 
were able to identify a likely pathogenic homozygous variant in PLOD3. 
Homozygosity mapping 
Whole genome-wide single nucleotide polymorphism (SNP)-based homozygosity mapping was 
performed by Infinium® Global Screening Array-24 v1.0 Kit (~640,000 SNP markers) using 
200 ng of genomic DNA as described by the manufacturer (Illumina,). The SNP genotyping data 
were analyzed by using PLINK (http://pngu.mgh.harvard.edu/). The Runs of Homozygosity 
algorithm in PLINK was used to identify ROH. The PLINK default values are appropriate for 
finding large segments of ROH present on dense genotyping platforms and were unchanged 
during the analysis. The PLINK output was filtered to eliminate ROH less than 4 Mb. ROH were 
compared in proband and his parents, and only those ROH present in the affected patient but not 
in the parents were considered as probable ROH harboring causal mutations. (For technical 
details of HM, see [32, 33]) 
Cell culture and LH3 expression analysis:  
Primary dermal fibroblast cultures of the patient and controls were established from a skin 
biopsy and were grown under standard conditions including DMEM (Dulbecco's Modified Eagle 
Medium) and 10% fetal bovine serum (FBS). Total RNA was extracted in triplicate from 
cultured cells derived from the patient and controls using the RNeasy mini kit (Qiagen, Hilden, 
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Germany) with on-column DNase digestion (Qiagen) according to the manufacturer’s 
instructions. cDNA was synthesized from 1 μg of mRNA using the iScript cDNA synthesis kit 
(Bio-Rad Laboratories, Hercules, CA, USA), followed by reverse transcription quantitative real-
time PCR (RT-qPCR) amplification. The expression level was determined for the PLOD3 gene 
using the reference genes HPRT1, YWHAZ, and RPL13A for normalization (primers and 
conditions available on request). Each sample was analysed in duplicate and data analysis was 
performed with the qBasePlus software (Biogazelle, Ghent, Belgium).  
Transcriptome profiling of collagen gene expression by heatmap analysis  
Total RNA was extracted from the fibroblast obtained from the patient and a healthy controls 
using TRIzol® Reagent and quantified on a Nanodrop ND-100 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE), followed by RNA quality assessment on an Agilent 2200 
TapeStation (Agilent Technologies, Palo Alto, CA). Multiplexed library construction, workflow 
analysis, and sequencing runs were performed following standard Illumina protocols (Illumina, 
Inc., San Diego, CA) using the TruSeq Stranded Total RNA kit with indexes from Set A (Cat #: 
RS-122-2301). Paired-end (2 × 75) sequencing reads were generated on the Illumina NextSeq 
500 platform and stored in FASTQ format. FASTQ quality was checked using FastQC, and the 
TruSeq RNA adapter sequences were removed by Trimmomatic. Alignment and mapping were 
performed using STAR-2pass (v. 2.5.3a) [34] with the human reference genome (GRCh38/hg38) 
and GENCODE V27 annotations. In the first pass, an initial alignment was executed and the 
splice junction information was collected. This information was then used for the second pass in 
which the final alignment was performed. The alignments were sorted, read group was added, 
and the corresponding index was created (using Picard tools).  
Western blotting 
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Cell lysates were collected from dermal fibroblast cultures using RIPA lysis buffer (Sigma–
Aldrich) complemented with protease (Roche) and phosphatase (Sigma–Aldrich) inhibitors and 
subjected to SDS-PAGE on 4-12% Bis-Tris gel (Invitrogen, Thermo Fisher Scientific). 
Subsequently, proteins were transferred to a nitrocellulose membrane using the iBlot System 
(Thermo Fisher Scientific) and immunolabeled with PLOD3 Rabbit Polyclonal antibody (1:500, 
Proteintech Europe, Manchester, United Kingdom) and horseradish peroxidase (HRP) 
conjugated secondary antibody (Cell Signaling Technologies, Danvers, MA, USA). Membranes 
were developed using the SuperSignal West Dura Extended Duration Substrate kit (Thermo 
Fisher Scientific, Life Technologies Europe, Ghent, Belgium) and scanned with the Amersham 
Imager 680 (GE Healthcare Life Sciences). Following stripping, the membrane was reprobed 
with β-tubulin (Abcam, Cambridge, United Kingdom) in order to check for equal loading. This 
analysis was repeated three times. Intensity of the bands was quantified using the ImageJ 
software. 
Measurements of urinary hydroxylysine derivatives 
Urine samples were collected from proband and his parents. Urine samples and isolated peptide 
fractions were acid hydrolyzed and analyzed by reverse phase HPLC as previously described 
(Kraenzlin et al., 2008). To allow for the detection of galactosyl-hydroxylysylpyridinoline 
(GHL) and glucosyl-galactosyl-hydroxylysine (GGHL), as pyridinoline compounds derived from 
collagen crosslinks, samples were analyzed also without prior acid hydrolysis. 
Immunofluorescence staining 
Skin sections (5 μm) were air-dried and initially blocked with diluted normal goat serum (Sigma-
Aldrich, Dorset, UK), and then incubated with anti-LH3 antibody diluted 1:10 in phosphate-
buffered saline with 30% w/v bovine serum albumin (Sigma-Aldrich). After washing in 
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phosphate-buffered saline, slides were labeled with fluorescein isothiocyanate secondary 
antibodies (Invitrogen, Paisley, UK). Negative controls omitting the primary antibody were also 
performed. All sections were photographed using the same camera and identical exposure times 
(3 seconds). A list of antibodies used for characterization of the skin from the proband with 
homozygous PLOD3 mutation can be found in Supplementary Table S3. 
Mean Fluorescence Intensity 
Mean Fluorescence Intensity (MFI) was calculated for each IF section using Image J 
(http://rsb.info.nih.gov/ij/). Ten measurements were taken at regular intervals using 8x8 pixels 
every 100 pixel along the dermal-epidermal junction. The values are presented as mean + 
standard error of mean (SE) as well as a percent of the staining intensity in the skin of a healthy, 
unrelated control (100%). 
Transmission electron microscopy 
Skin biopsy specimens were cut into small pieces (<1 mm
3
) and fixed in half-strength Karnovsky 
fixative for 4 hours at room temperature. After washing in 0.1 M phosphate buffer (pH 7.4), the 
samples were immersed in 1.3% aqueous osmium tetroxide (TAAB Laboratories, Berkshire, 
UK) for 2 hours, followed by incubation in 2% uranyl acetate (Bio-Rad, Hertfordshire, UK), and 
dehydrated in a graded ethanol series, and then embedded in epoxy resin via propylene oxide 
(TAAB Laboratories). Ultra-thin sections were stained with uranyl acetate and lead citrate and 
examined in a Philips CM10 transmission electron microscope (Philips, Eindhoven, The 
Netherlands). 
LH3 protein modeling 
Three-dimensional structure of LH3 was adopted from a published study [35] (PDB entry: 
6FXR). Molecular graphics were visualized using VMD version 1.9.3 [36]. 
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Figure Legend 
Figure 1. Family pedigree and clinical features of the proband. (a) The proband (arrowhead) was 
born to clinically healthy parents who are first cousins once removed. (b, c) Note the presence of 
a tense, hemorrhagic blister on the fifth toe and small erosions on arm (white arrows) with 
evidence of atrophic scarring at the elbow. (d) Chest X-ray demonstrating the diaphragmatic 
eventration. (e, f) Presence of contractions on the elbow and the digits on the left hand. (g, h). 
Presence of severe scoliosis noted clinically and confirmed by MRI.  
 
Figure 2. Identification of homozygous PLOD3 mutation. (a) Homozygosity mapping revealed a 
~45 Mb region of homozygosity in the proband (V-2), which was not present in the parents (IV-
1, IV-2); this region on chromosome 7 contained the locus for PLOD3. (b) Whole exome 
sequencing identified a total of ~134,000 annotated sequence variants which were filtered by 
steps indicated to yield 16 variants with minor allelic frequency (MAF) of <1:1,000. Eight of 
these variants were within the different regions of homozygosity as shown in (a), and matching 
the phenotype of the patient identified a mutation in PLOD3. The homozygous mutation in the 
patient, p.Leu627Pro, was confirmed by Sanger sequencing (right upper panel) and the parents 
were heterozygous carriers of the mutation (lower panel). (d) Three-dimensional structure of 
LH3. The p.Leu627Pro mutation within the lysyl hydroxylase (LH) domain is presented in red. 
Previously reported p.Asn223Ser missense mutation in glycosyltransferase (GT) domain is 
depicted in purple and frameshift mutation (p.Cys691AlafsX9) results in deletion of 40 amino 
acid residues at the end of C-terminus of the protein colored in yellow. Ferrous iron molecules 
are shown as brown spheres, and 2-oxoglutarate as black CPK representation. (e and f) Western 
blotting revealed markedly reduced LH3 protein levels in fibroblasts cultured from the skin of 
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the patient (P) as compared to controls (C1-3). Reprobing the filter with an anti--tubulin 
antibody revealed equal protein loading. The LH3 protein levels were quantitated by scanning 
the bands in Western blots in three separate experiments (mean + SEM; **p<0.01, ***p<0.001). 
(g) Heatmap based transcriptome expression profiling of fibroblast obtained from patient 
revealed significantly reduced COL7A1 mRNA levels in comparison to several randomly 
selected housekeeping genes. No significant difference was observed in gene expressions of 
PLOD3 and types I, IV, V, and VI collagens. 
  
 
Figure 3. Demonstration of sub-lamina densa tissue separation in the skin of the proband. (a) 
Histopathology reveals separation at the dermal-epidermal junction (Richardson’s stain). (b) 
Transmission electron microscopy reveals that the blister formation is below the lamina densa 
which is delineated by arrows. (Blister marked by an asterisk). 
 
Figure 4. Transmission electron microscopy of patient skin reveals fragmentation of the lamina 
densa. (a) The lamina densa within the right half of this skin section appears intact but on the left 
half it is interrupted and fragmented. (b) Patchy areas of intact lamina densa are present (arrows) 
below which there is some sub-lamina densa cleavage (asterisks). (c) In the superficial dermis, 
there are fibroblasts (arrows) close to the dermal-epidermal junction that display dilated 
endoplasmic reticulum and prominent vesicles close to the cell membrane, with some adjacent 
dermal cleavage (asterisk). 
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Figure 5. Demonstration of fibrosis in the upper dermis of the skin of the proband. (a) 
Histopathology at lower magnification reveals a homogeneous fibrotic zone in the upper dermis. 
(b) Higher magnification reveals a number of fibroblastic cells in the upper papillary dermis 
juxtaposed to the dermal-epidermal junction. (c) Transmission electron microscopy of the upper 
dermis reveals the presence of fibroblastic cells with dilated cisternae of rough endoplasmic 
reticulum, embedded in dense collagenous meshwork (a, b: Richardson’s stain). 
 
Figure 6. Transmission electron microscopy reveals variations in the number and morphology of 
anchoring fibrils of the proband’s skin. (a) In some areas, anchoring fibrils with normal 
appearance are present (arrows). (b) In some areas, the anchoring fibrils are wispy, hypoplastic 
and reduced in number. (c, d) Anchoring fibrils are absent in areas of blistering (asterisks).  
 
Figure 7. Immunofluorescence analysis and immuno-epitope mapping of the location of the 
blistering in the skin of the proband. (a) Immunofluorescence reveals complete absence of LH3 
in the patient’s skin with a blister (asterisk), while in the control skin, a punctate pattern at the 
dermal-epidermal junction is noted. Type VII collagen expression is significantly reduced, the 
remaining protein being primarily in the roof of the blister. Type IV collagen staining reveals 
normal amounts of protein at the dermal-epidermal junction primarily in the roof of the blister. 
The staining on the floor of the blister is attributable to neovascularization as part of the 
regenerative fibrotic process. (b) Immunofluorescence reveals attenuated intensity of staining 
with antibodies to type XVII collagen and plectin, while laminin-332 and 4 integrin staining is 
of normal intensity and primarily in the roof of the blister. (c) Staining for different keratins 
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reveals somewhat attenuated staining patterns presumably reflecting overall perturbation of the 
structure at the basement membrane zone. (Scale bar = 50 m). 
 
Figure 8. Demonstration of reduced type VII collagen expression in the skin of the proband by 
Mean Fluorescent Intensity (MFI) analysis using Image J (National Institutes of Health, 
Bethesda, MD). (a) Biopsies were obtained from different areas of skin and stained for type VII 
collagen (Images I-IV). (b) The intensity of the staining was morphometrically quantitated and 
calculated as a percent of the staining intensity in the skin of a healthy, unrelated control. (c) 
Graphical representation of MFI for type VII collagen expression in the skin of the proband 
compared to an unrelated control. Each bar represents the mean value of 10 measurements of 
type VII collagen expression intensity along the dermal-epidermal junction from corresponding 
images (I-IV); error bars represent standard error of the mean. 
 
Figure 9. Analysis of the lysine (L), hydroxylysine (HL) and its glycosylated derivatives 
(glucosyl-galactosyl hydroxylysine, GGHL; and glucosyl hydroxylysine, GHL), analyzed in the 
urine of the patient and his parents as pyridinoline compounds. The peaks represent: 1, GGHL; 2, 
GHL; 3, HL; 4,L; IS, internal standard in the liquid chromatography. The values were calculated 
from the area under each peak as a percent of total (mean of two independent measurements). 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
34 
 
Highlights 
 Recessive dystrophic epidermolysis bullosa is caused by mutations in COL7A1 
 We have evaluated a patient with multisystem disorder including blistering phenotype 
 NGS identified mutations in PLOD3 encoding lysyl hydroxylase 3 (LH3) 
 The mutant LH3 was associated with reduced type VII collagen and anchoring fibrils 
 PLOD3 is the second mutant gene associated with RDEB 
ACCEPTED MANUSCRIPT
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
